Cipla Limited
Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, suc… Read more
Market Cap & Net Worth: Cipla Limited (CIPLA)
Cipla Limited (NSE:CIPLA) has a market capitalization of $12.26 Billion (₹1.06 Trillion) as of March 18, 2026. Listed on the NSE stock exchange, this India-based company holds position #1873 globally and #36 in its home market, demonstrating a -0.88% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cipla Limited's stock price ₹1314.70 by its total outstanding shares 807780677 (807.78 Million).
Cipla Limited Market Cap History: 2015 to 2026
Cipla Limited's market capitalization history from 2015 to 2026. Data shows growth from $5.81 Billion to $12.26 Billion (6.92% CAGR).
Index Memberships
Cipla Limited is a constituent of 9 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NIFTY PHARMA
CNXPHARMA
|
$58.09 Billion | 14.72% | #1 of 20 |
|
NIFTY GROWTH SECTORS 15
NI15
|
$148.64 Billion | 5.75% | #7 of 15 |
|
NIFTY 100
NIFTY100
|
$802.80 Billion | 1.07% | #32 of 100 |
|
NIFTY100 EQUAL WEIGHT
NIFTY100EW
|
$734.02 Billion | 1.17% | #27 of 99 |
|
NIFTY 200
NIFTY200
|
$1.08 Trillion | 0.79% | #33 of 200 |
|
NIFTY 500
NIFTY500
|
$1.33 Trillion | 0.64% | #33 of 500 |
|
NIFTY HEALTHCARE
NIFTYHEALTHCARE
|
$72.50 Billion | 11.80% | #2 of 20 |
|
Nifty Low Volatility 50
NIFTYLVI
|
$454.91 Billion | 1.88% | #16 of 48 |
|
NIFTY TOTAL MARKET
NIFTYTOTALMKT
|
$1.39 Trillion | 0.62% | #33 of 750 |
Weight: Cipla Limited's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Cipla Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cipla Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.05x
Cipla Limited's market cap is 0.05 times its annual revenue
1.01x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.27x
Cipla Limited's market cap is 0.27 times its annual earnings
10.29x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $5.06 Billion | $135.48 Billion | $13.60 Billion | 0.04x | 0.37x |
| 2017 | $5.44 Billion | $143.34 Billion | $10.06 Billion | 0.04x | 0.54x |
| 2018 | $4.67 Billion | $151.05 Billion | $14.11 Billion | 0.03x | 0.33x |
| 2019 | $4.33 Billion | $163.23 Billion | $15.28 Billion | 0.03x | 0.28x |
| 2020 | $7.43 Billion | $170.81 Billion | $15.47 Billion | 0.04x | 0.48x |
| 2021 | $8.62 Billion | $191.21 Billion | $24.05 Billion | 0.05x | 0.36x |
| 2022 | $9.88 Billion | $217.08 Billion | $25.17 Billion | 0.05x | 0.39x |
| 2023 | $11.56 Billion | $225.59 Billion | $28.02 Billion | 0.05x | 0.41x |
| 2024 | $14.26 Billion | $255.37 Billion | $41.22 Billion | 0.06x | 0.35x |
| 2025 | $14.10 Billion | $272.67 Billion | $52.73 Billion | 0.05x | 0.27x |
Competitor Companies of CIPLA by Market Capitalization
Companies near Cipla Limited in the global market cap rankings as of March 18, 2026.
Key companies related to Cipla Limited by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #423 globally with a market cap of $51.97 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #455 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #423 | Zoetis Inc | NYSE:ZTS | $51.97 Billion | $118.15 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.46 |
| #455 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Cipla Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, Cipla Limited's market cap moved from $5.81 Billion to $ 12.26 Billion, with a yearly change of 6.92%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₹12.26 Billion | -13.01% |
| 2025 | ₹14.10 Billion | -1.16% |
| 2024 | ₹14.26 Billion | +23.36% |
| 2023 | ₹11.56 Billion | +17.02% |
| 2022 | ₹9.88 Billion | +14.64% |
| 2021 | ₹8.62 Billion | +15.92% |
| 2020 | ₹7.43 Billion | +71.79% |
| 2019 | ₹4.33 Billion | -7.38% |
| 2018 | ₹4.67 Billion | -14.08% |
| 2017 | ₹5.44 Billion | +7.43% |
| 2016 | ₹5.06 Billion | -12.83% |
| 2015 | ₹5.81 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Cipla Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $12.26 Billion USD |
| MoneyControl | $12.26 Billion USD |
| MarketWatch | $12.26 Billion USD |
| marketcap.company | $12.26 Billion USD |
| Reuters | $12.26 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.